The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | How does P-32 microparticle brachytherapy compare with other locoregional techniques in uLAPC?
Michele Milella, MD, University of Verona, Verona, Italy, discusses how targeted intratumoral brachytherapy with phosphorus-32 (P-32) microparticles compares with external beam radiotherapy and stereotactic beam radiotherapy in unresectable locally advanced pancreatic cancer (uLAPC). Radiotherapy has not yet demonstrated a survival benefit when combined with chemotherapy for uLAPC, but does improve local control. Brachytherapy with P-32 demonstrates a potential advantage to conventional radiotherapy techniques by allowing a high delivery of radiation inside the tumor and as a beta emitter, P-32 does not damage surrounding tissue. Prof. Milella also discusses lesion selection and how the treatment approach can be tailored to the type of lesion. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
